Journal of Clinical Oncology, Vol 12, 1050-1057, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group

L Kaizer, D Warr, P Hoskins, J Latreille, W Lofters, J Yau, M Palmer, B Zee, M Levy and J Pater
Department of Medicine, Credit Valley Hospital, Mississauga; Ontario, Canada.

PURPOSE: This study examines whether the schedule of ondansetron significantly influences its antiemetic efficacy in the first 24 hours after chemotherapy, whether the administration of oral ondansetron after 24 hours is effective in preventing delayed emesis, and whether the efficacy of ondansetron is preserved over multiple courses of moderately emetogenic chemotherapy. PATIENTS AND METHODS: A multicenter double-blind study randomized 302 cancer patients to one of three treatment arms. Arm A received dexamethasone 10 mg intravenously (i.v.) plus ondansetron (Zofran; Glaxo Canada Inc, Toronto, Canada) 8 mg i.v. prechemotherapy plus ondansetron 8 mg orally every 12 hours postchemotherapy for nine doses. Arm B received dexamethasone 10 mg i.v. plus ondansetron 16 mg i.v. prechemotherapy plus placebo orally postchemotherapy in the same schedule as arm A. Arm C received dexamethasone 10 mg i.v. plus ondansetron 8 mg prechemotherapy plus ondansetron 8 mg orally postchemotherapy for one dose followed by placebo orally every 12 hours for eight more doses. Response was assessed by the number of reported episodes of vomiting and by severity of nausea measured on a visual analog scale (VAS). RESULTS: The two schedules of ondansetron used in the first 24 hours were no different in their antiemetic efficacy, with similar rates for complete responses (76.7% v 72.0%, P = .472), complete plus major responses (90.2% v 82.0%, P = .135), and severity of nausea (P = .348). Oral ondansetron after 24 hours was more effective than placebo in preventing delayed nausea and emesis, with superior rates of complete responses (59.6% v 42.1%, P = .012 by one-sided test), complete plus major responses (80.9% v 66.3%, P = .018 by one-sided test), and less severe nausea (9.2 mm v 18.6 mm on a 100-mm VAS, P = .002). The efficacy of ondansetron was maintained over subsequent courses of chemotherapy. CONCLUSION: The schedule of ondansetron in the first 24 hours does not influence its efficacy. The use of oral maintenance ondansetron is effective in preventing delayed maintenance ondansetron is effective in preventing delayed nausea and emesis after moderately emetogenic chemotherapy.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Y. Segawa, K. Aogi, K. Inoue, M. Sano, I. Sekine, Y. Tokuda, H. Isobe, T. Ogura, M. Tsuboi, S. Atagi, et al. A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy Ann. Onc., November 1, 2009; 20(11): 1874 - 1880. [Abstract] [Full Text] [PDF]

				M. Aapro, S. Grunberg, G. Manikhas, G Olivares, T Suarez, S. Tjulandin, L. Bertoli, F Yunus, B Morrica, F Lordick, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Ann. Onc., September 1, 2006; 17(9): 1441 - 1449. [Abstract] [Full Text] [PDF]

				M. G. Kris, P. J. Hesketh, M. R. Somerfield, P. Feyer, R. Clark-Snow, J. M. Koeller, G. R. Morrow, L. W. Chinnery, M. J. Chesney, R. J. Gralla, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006 J. Clin. Oncol., June 20, 2006; 24(18): 2932 - 2947. [Abstract] [Full Text] [PDF]

				D. G. Warr, P. J. Hesketh, R. J. Gralla, H. B. Muss, J. Herrstedt, P. D. Eisenberg, H. Raftopoulos, S. M. Grunberg, M. Gabriel, A. Rodgers, et al. Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy J. Clin. Oncol., April 20, 2005; 23(12): 2822 - 2830. [Abstract] [Full Text] [PDF]

				O. Geling and H.-G. Eichler Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications J. Clin. Oncol., February 20, 2005; 23(6): 1289 - 1294. [Abstract] [Full Text] [PDF]

				A. M Massaro and K. L Lenz Aprepitant: A Novel Antiemetic for Chemotherapy-Induced Nausea and Vomiting Ann. Pharmacother., January 1, 2005; 39(1): 77 - 85. [Abstract] [Full Text] [PDF]

				R. Gralla, M. Lichinitser, S. Van der Vegt, H. Sleeboom, J. Mezger, C. Peschel, G. Tonini, R. Labianca, A. Macciocchi, and M. Aapro Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann. Onc., October 1, 2003; 14(10): 1570 - 1577. [Abstract] [Full Text] [PDF]

				T. Sigsgaard, J. Herrstedt, J. Handberg, M. Kjar, and P. Dombernowsky Ondansetron Plus Metopimazine Compared With Ondansetron Plus Metopimazine Plus Prednisolone as Antiemetic Prophylaxis in Patients Receiving Multiple Cycles of Moderately Emetogenic Chemotherapy J. Clin. Oncol., April 1, 2001; 19(7): 2091 - 2097. [Abstract] [Full Text] [PDF]

				M. S. Copur, P. Ledakis, M. Norvell, D. Harmon, B. O'Brien, F. Roila, E. Ballatori, and A. Del Favero Prevention of Delayed Emesis Caused by Chemotherapy N. Engl. J. Med., September 21, 2000; 343(12): 888 - 890. [Full Text]

				The Italian Group for Antiemetic Research Dexamethasone Alone or in Combination with Ondansetron for the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy N. Engl. J. Med., May 25, 2000; 342(21): 1554 - 1559. [Abstract] [Full Text] [PDF]

				R. J. Gralla, D. Osoba, M. G. Kris, P. Kirkbride, P. J. Hesketh, L. W. Chinnery, R. Clark-Snow, D. P. Gill, S. Groshen, S. Grunberg, et al. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., September 1, 1999; 17(9): 2971 - 2971. [Full Text] [PDF]

				R. M. Navari and P. J. Hesketh Use of Placebos in Delayed-Emesis Studies J. Clin. Oncol., May 1, 1999; 17(5): 1644 - 1644. [Full Text] [PDF]

				C. C. Gotay and M. Wilson Use of Quality-of-Life Outcome Assessments in Current Cancer Clinical Trials Eval Health Prof, June 1, 1998; 21(2): 157 - 178. [Abstract] [PDF]

				R. J. Ignoffo and R. King Pharmaceutical care and the cancer patient Journal of Oncology Pharmacy Practice, December 1, 1995; 1(4): 7 - 19. [Abstract] [PDF]